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Abstract: To investigate the anti-carcinogenic effects of Atorvastatin (Atorva) on a rat 
bladder carcinogenesis model with N-butyl-N-(4-hydroxibutil)nitrosamine (BBN), four 
male Wistar rat groups were studied: (1) Control: vehicle; (2) Atorva: 3 mg/kg bw/day;  
(3) Carcinogen: BBN (0.05%); (4) Preventive Atorva: 3 mg/kg bw/day Atorva + BBN.  
A two phase protocol was used, in which the drug and the carcinogen were given between 
week 1 and 8 and tumor development or chemoprevention were expressed between week  
9 and 20, when the bladders were collected for macroscopic, histological and 
immunohistochemical (p53, ki67, CD31) evaluation. Serum was assessed for markers of 
inflammation, proliferation and redox status. The incidence of bladder carcinoma was: 
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control 0/8 (0%); Atorva 0/8 (0%); BBN 13/20 (65%) and Atorva + BBN 1/8 (12.5%). The 
number and volume of tumors were significantly lower in the Atorva + BBN group, with a 
marked reduction in hyperplasia, dysplasia and carcinoma in situ lesions. An  
anti-proliferative, anti-inflammatory and antioxidant profile was also observed in the 
preventive Atorva group. p53 and ki67 immunostaining were significantly increased in the 
BBN-treated rats, which was prevented in the Atorva + BBN group. No differences were 
found for CD31 expression. In conclusion, Atorvastatin had a clear inhibitory effect on 
bladder cancer development, probably due to its antioxidant, anti-proliferative and  
anti-inflammatory properties. 
Keywords: bladder cancer; chemoprevention; atorvastatin; antioxidant; anti-proliferative; 
anti-inflammatory 
 
1. Introduction 
In developed nations, bladder cancer is the fourth most common tumor in men and the eighth in 
women, accounting for 5–10% of all malignancies in men [1]. It is associated with high incidence and 
prevalence rates, and elevated socioeconomic costs [2,3]. Furthermore, it presents high recurrence and 
progression rates are a poor prognosis, particularly when late diagnosed or inadequately  
treated [1,3,4]. Despite current efforts on earlier diagnosis and more aggressive treatments, mortality 
rates in muscle-invasive disease are still very high [5]. In this context, preventive strategies will be 
pivotal for the management and treatment of bladder cancer, which depends on a better elucidation of 
the molecular mechanisms underlying appearance and growth.  
Bladder tumor is associated with exogenous risk factors, which include mainly the cigarette 
smoking habit, present in more than 50% of the cases in the male population [3,6], and the exposure to 
occupational carcinogens, in particular aromatic amines and polycyclic aromatic hydrocarbons [6,7]. 
However, besides these risk factors and some genetic features already characterized [8,9], the putative 
involvement of inflammatory, proliferative and oxidative stress pathways deserve proper clarification. 
The rat bladder cancer induced by N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) is an appropriate 
and validated model to study human cancer development [10]. Due to the histological similarities with 
the human bladder cancer, it has been the most used model for the study of tumor pathophysiology, as 
well as to evaluate the efficacy of therapeutic strategies [10–12]. The urothelial carcinogenesis is a 
continuous and slow process that that goes through molecular and morphological changes, from benign 
to aggressive lesions. Thus, an early treatment targeting these pathways could hypothetically prevent 
bladder cancer development and growth. Previous reports have demonstrated beneficial effects of 
preventive strategies [13], including our own studies using anti-inflammatory and anti-proliferative 
agents [14,15]. 
During the last years, 3-hydroxy-3-methylglutaryl-coenzyme A (HMGCoA) reductase inhibitors 
(statins) have been indicated as potential anticancer agents [16–18]. Beyond their anti-dyslipidaemic 
properties, statins exhibit many other biological activities, known as pleiotropic effects [19]. Statins 
have been shown anti-inflammatory, anti-proliferative, antioxidant and anti-apoptotic properties [20–22], 
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which could have an important role in bladder tumor prevention [23], particularly when considering 
that these pathways are up-regulated in this type of cancer [14,15]. The chemopreventive efficacy of 
statins was already demonstrated in other types of tumors, including in the pancreatic and the prostate 
cancers, resulting in retardation of tumor growth and/or inhibition of the metastatic process [24,25]. 
However, its action in bladder cancer remains to be proved, deserving further research.  
Considering the beneficial effects of statins on the reduction for cardiovascular risk due to the 
antidyslipidemic effect, a positive impact against bladder cancer would be a major advantage, 
translating into a significant medical and socioeconomic benefit in patients that share several risk 
factors. Hence, this work intended to evaluate the chemopreventive efficacy of atorvastatin in a rat 
model of nitrosamine-induced bladder cancer.  
2. Results  
2.1. Bladder Cancer Development and Growth 
No relevant changes were detected between the groups throughout the study concerning body 
weight and beverage consumption (data not shown). The lungs, stomach, liver, kidneys and intestines 
were normal on gross inspection and on histological examination, confirming the specificity of this 
model for bladder cancer development. 
2.1.1. Macroscopic Evaluation 
All bladders from the control animals were normal (Figure 1A). Similar profile was found for the 
Atorva group, with translucent and tiny bladders, without any abnormal mass or vascularization 
(Figure 1B). In the BBN group, however, 65.0% (13 in 20) of the rats had grossly visible bladder 
tumors, some of them of large dimensions (Figure 1C). The bladder walls were thicker than those of 
the control rats, with new or enlarged small vessels. In the Atorva + BBN group, all but one bladder 
showed a pattern similar to those of the controls (Figure 1D), the remaining bladder showing  
2 small tumors.  
2.1.2. Quantitative Evaluation 
In the control and Atorva groups, no tumors were seen. In the BBN group, 16 tumors were detected 
in 13 rats (with a mean of 1.2 ± 0.1 tumors per rat with tumor). In these 13 rats, the mean tumor 
volume was 138.5 ± 7.5 mm3 and the mean tumor volume per tumor was 112.5 ± 6.4 mm3 (Table 1).  
In the Atorva + BBN group, 1 (12.5%) of the 8 rats had 2 tumors with a summed volume of 4.7 mm3 
and a mean tumor volume per tumor of 2.3 ± 0.2 mm3 (Table 1). 
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Figure 1. Macroscopic histomorphological evaluation of bladders, from the groups  
under study: (A) Control; (B) Atorva; (C) N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN);  
(D) Atorva + BBN. 
A C
B D
 
Table 1. Macroscopic and microscopic evaluation of urothelial lesions. 
Macroscopy 
(quantitative) 
Control 
(n = 8) 
Atorva 
(n = 8) 
BBN 
(n = 20) 
Atorva + BBN 
(n = 8) 
Tumor number     
% rats with tumor 0 0 65.0% (13 in 20) 12.5% (1 in 8) 
Number tumors/rat 0 0 1.2  0.1 (16 in 13) 2.0 (2 in 1) 
Tumor volume (mm3):     
Mean/rat 0 0 138.5 ± 7.5 (in 13) 4.7 (in 1) 
Mean/tumor 0 0 112.5 ± 6.4 (in 16) 2.3 ± 0.2 (in 2) 
Microscopy 
(qualitative) 
Control Atorva  BBN Atorva + BBN 
   
Tumors  
Group 
Total  
Group 
Tumors 
Group 
Total 
Group 
Pre-neoplastic lesions       
Hyperplasia 0 0 100 (13/13) 100 (20/20) 100 (1/1) 38 (3/8) 
High-grade dysplasia 0 0 100 (13/13) 75 (15/20) 100 (1/1) 13 (1/8) 
Low-grade dysplasia 0 0 0 (0/13) 25 (5/20) 0 (0/1) 25 (2/8) 
Neoplastic lesions       
Papillary tumor 0 0 100 (13/13) 65 (13/20) 100 (1/1) 13 (2/8) 
Infiltrative tumor 0 0 15 (2/13) 10 (2/20) 0 (0/1) 0 (0/8) 
Carcinoma in situ 0 0 31 (4/13) 20 (4/20) 0 (0/1) 0 (0/8) 
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2.1.3. Qualitative Evaluation 
Histological evaluation showed a normal urothelium in the control and in the Atorva rats  
(Figure 2A,B, respectively). No pre-neoplastic lesions (hyperplasia or dysplasia) were found (Table 1). 
In the carcinogen (BBN) group, there was evident malignant transformation, including hyperplasia 
(100%) and dysplasia (100%), present in all the animals, including those without tumors (Table 1 and 
Figure 2C1). Furthermore, there were also malignant lesions: papillary, infiltrative and carcinoma  
in situ (CIS) (Table 1 and Figure 2C2). The use of Atorvastatin (Atorva + BBN group) prevented 
bladder cancer development. Only one bladder (12.5%) of the 8 rats from this group has presented 
cancer development: two papillary tumors (Table 1). Histology also showed hyperplasia and dysplasia 
but no CIS or infiltrative lesions were identified (Table 1 and Figure 2D2). None of the other rats  
from this group had pre-malignant lesions and hyperplasia was found in only one case (Table 1 and  
Figure 2D1).  
Figure 2. Microscopic histomorphology evaluation of bladders, from the groups under 
study: (A) Control; (B) Atorva; (C1 and C2) BBN; (D1 and D2) Atorva + BBN. H & E 
staining (100×). 
B
C1
A
C2
D1 D2
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2.2. Systemic Proliferation, Inflammation and Oxidative Stress Markers 
In the BBN group there was a significant increment in serum transforming growth factor beta-1 
(TGF-β1) (p < 0.01) and C-reactive protein (CRP) (p < 0.001), when compared with the control group 
(Figure 3A,B, respectively). Serum tumor necrosis factor alpha (TNF-α) levels were unchanged 
between BBN and control rats, despite a trend to higher values in the carcinogen group (Figure 3C). 
Compared to the control group, the Atorva-treated rats showed reduced concentrations of TGF-β1 and 
CRP (p < 0.001), whereas TNF-α was unchanged (Figure 3). In the Atorva + BBN group, the  
BBN-induced increment of serum levels of TGF-β1 and CRP was totally prevented (p < 0.001), 
together with a significant (p < 0.001) reduction of TNF-α contents (Figure 3). 
Figure 3. Serum markers of proliferation and inflammation. (A) TGF-β1; (B) CRPhs;  
(C) TNF-α. Values are mean ± SEM. a: p < 0.05 and aaa: p < 0.001 vs. Control group;  
bbb: p < 0.001 vs. BBN group.  
 
Although non-statistically significant, serum malondialdehyde (MDA) concentration showed a 
trend to higher values in the BBN group when compared with the control, which was accompanied by 
a significant increase (p < 0.05) in serum total antioxidant status (TAS). In agreement, serum 
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MDA/TAS ratio, a redox status marker, was unaltered (Figure 4). In the Atorva group, while serum 
MDA showed a trend to increased concentrations, there was a significant increase (p < 0.01) in serum 
TAS, accompanied by a significant reduction (p < 0.05) of serum MDA/TAS ratio, versus the control 
rats. Similar antioxidant profile was found for the Atorva + BBN group vs. BBN, in which there were 
significantly higher values of TAS (p < 0.01) and unchanged of MDA, resulting in a significantly 
lower ratio MDA/TAS (p < 0.05), demonstrative of an antioxidant profile (Figure 4). 
Figure 4. Serum redox status markers. (A) Lipidic peroxidation, via MDA content;  
(B) TAS levels; (C) MDA/TAS ratio. Values are mean ± SEM. a: p < 0.05, aa: p < 0.01 vs. 
Control group; b: p < 0.05, bb: p < 0.01 vs. BBN group. 
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2.3. Bladder Cancer p53, ki67 and CD31 Immunohistochemistry 
The bladders from control (Figure 5A) and Atorva (Figure 5B) treated-rats presented normal p53 
immunostaining intensity (grade 1). However, in the BBN group, both the hyperplastic (Figure 5C1) 
and tumoral (Figure 5C2) lesions showed elevated expression of p53 (grade 3 intensity). In the  
Atorva + BBN rats, all the bladders with normal urothelium (Figure 5D1) showed a p53 
immunostaining identical to the control bladders (grade 1). The bladder with cancer (Figure 5D2) 
showed more intense p53 expression (grade 2) than those of the same group without tumor but lower 
intensity than those of the BBN rats. 
Figure 5. Bladder cancer p53 immunostaining, for the groups under study: (A) Control;  
(B) Atorva; (C1 and C2) BBN; (D1 and D2) Atorva + BBN. Original magnification 100× 
(A, B and D1) and 200× (C1, C2 and D2). 
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Regarding ki67 expression, reduced percentage of ki67 immunostaining was found in both the 
bladders from control (Figure 6A) and Atorva (Figure 6B) treated-rats (grade 0). In contrast, in the 
BBN group, the hyperplastic lesions (Figure 6C1) presented higher percentage of ki67 immunostaining 
(grade 1), which was even superior (grade 2) in the tumoral lesions (Figure 6C2). This pattern was 
prevented in the Atorva + BBN rats, with all bladders showing reduced ki67 expression: a low 
percentage (grade 0) was found in the bladders without tumor and a grade 1 in the bladder with tumours 
(Figure 6D1,D2, respectively). We did not find significant differences in CD31 (PECAM-1) expression 
among the groups under study (data not shown). 
Figure 6. Bladder cancer ki67 immunostaining, for the groups under study: (A) Control; 
(B) Atorva; (C1 and C2) BBN; (D1 and D2) Atorva + BBN; Original magnification 100× 
(A, C2 and D1) and 200× (B, C1 and D2). 
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2.4. Biochemical Data: Safety Profile 
In the BBN group, renal function markers (creatinine and urea) were unchanged; the liver function 
parameter AST was significantly (p < 0.001) increased; and there was a trend to higher values of 
creatine kinase (CK), when compared with the control group (Table 2). The Atorva group had a 
significant (p < 0.05) increase in CK activity versus the control group. In the Atorva + BBN group, the 
renal markers remained unchanged but there was an increment in AST and ALT (p < 0.001 and  
p < 0.01 vs. BBN, respectively), together with a higher CK value (p < 0.001 vs. BBN) (Table 2).  
Table 2. Safety profile: renal and liver function data and creatine kinase activity. 
Parameters 
Control 
(n = 8) 
Atorva 
(n = 8) 
BBN 
(n = 20) 
Atorva + BBN  
(n = 8) 
Renal function 
  Creatinine (µmol/L) 50.39 ± 0.88 56.57 ± 0.88 54.81 ± 1.77 59.23 ± 3.54 
  Urea (mmol/L) 6.40 ± 0.31 5.99 ± 0.32 6.27 ± 0.16 6.85 ± 0.24 
Liver function 
  AST (IU/L) 51.57 ± 1.09 54.00 ± 2.31 76.78 ± 4.40 aaa 111.25 ± 5.72 bbb 
  ALT (IU/L) 30.86 ± 1.75 31.00 ± 1.00 36.17 ± 2.32 53.43 ± 6.10 bb 
CK activity (U/L) 165.80 ± 14.60 697.67 ± 59.22 a 231.88 ± 8.22 1132.17 ± 206.39 bbb 
Values are mean ± s.e.m. a p < 0.05 and aaa p < 0.001 vs. the Control group; bb p < 0.01 and  
bbb p< 0.001 vs. the BBN group. 
3. Discussion  
During the last years, statins have been indicated as potential anticancer agents beyond their typical 
antihyperlipidaemic actions [16–18], particularly because of their pleiotropic effects [19]. Some 
medical-record database studies have shown significant statin-associated reductions in overall cancer 
incidence [16]. The chemoprevention properties of these drugs have been tested, with promising 
results, in several types of cancer [24–27]. However, investigation on its efficacy in bladder cancer 
prevention is almost non-existent [28]. Older and hyperlipidaemia patients are most effected by 
bladder cancer. Moreover, untreated hyperlipidaemia is associated not only with increased risk of 
bladder cancer development [29] but also with more aggressive forms [30]. Thus, if proved its 
anticancer properties, the preventive use of statins for those patients could have a double benefit, 
preventing both hypercholesterolaemia and cancer, namely bladder cancer.  
The main finding of our study, not previously shown in any animal model (or in humans) is that 
tumor growth is inhibited by Atorva treatment. We found in the BBN + Atorva animals a tumour 
incidence of 12.5% (1 in 8 rats) with a mean tumor volume per tumor of 2.3 ± 0.2 mm3, contrasting 
with the data from the BBN rats: 65% incidence and 112.5 ± 6.4 mm3 mean tumor volume  
(in 16 tumors of 13 rats with tumor). Furthermore, apart from the rat with tumor, whose urothelium 
also showed hyperplasia and low-grade dysplasia, all other rats of the BBN + Atorva group had a 
normal urothelium (one of them showed low-grade hyperplasia). The hyperplasia and high-grade 
dysplasia induced by the carcinogen, present in all BBN-treated animals, were significantly reduced in 
the Atorva group, to 38% and 25%, respectively, together with an absolute prevention of infiltrative 
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tumors and CIS. These data reinforces the notion that this drug is effective not only for 
chemoprevention of gross tumor appearance and growth but also for prevention of pre-neoplastic lesions. 
This remarkable chemopreventive efficacy on tumor growth was achieved with what might be 
considered a low Atorva dose for animal studies (considering their pharmacokinetic differences with 
humans). This dosage is similar to the low-doses used in other recent studies with atorvastatin [31–33], 
reinforcing the promising results. Nevertheless, future research should confirm the drug blood 
concentrations achieved in order to assess their efficacy in bladder cancer in humans. Apart from the 
expected increment in CK activity, and some deterioration of hepatic (AST and ALT) markers, which 
may be due to the amplification of the carcinogen effects, Atorva treatment, particularly at low-doses, 
is unlikely to be associated with an unsafe profile. In any case, the elevations of CK and hepatic 
markers raise some concerns about the safety profile and deserve further study, including assessing if 
even lower doses of Atorvastatin in this animal model will be able to maintain the chemopreventive 
efficacy with a safe profile. Statins have a well known safety profile in the clinical setting, which is a 
clear advantage over other potential anti-carcinogen agents. Clinical trials have shown that statins are 
relatively well tolerated; therefore, gastrointestinal symptoms, abnormal liver enzyme levels and 
myalgia and/or myositis being the main side effects, occurring in a small percentage of the patients [34]. 
Several studies have proposed distinct cellular/molecular mechanisms to explain the chemopreventive 
effects of this group of compounds, particularly in other cancer types, such as the pancreatic and the 
prostate cancer, including the action on cell cycle and the induction of apoptosis and growth 
suppression [35–37]. Not excluding other eventually relevant contributions, such as the modulation of 
Ras and Rho proteins by statins-induced mevalonate depletion [38,39], our data suggest that Atorva 
use is able to promote cancer chemoprevention by anti-proliferative, anti-inflammatory and antioxidant 
actions. Serum TGF-β1, TNF-α and CRP levels were highly reduced when compared with the 
carcinogen (BBN) group. The anti-proliferative effect of atorvastatin was already demonstrated in two 
human transitional cell carcinoma cell lines (RT4 and KU-7) [28], as well as in a rat model of liver 
cancer [40]. Statins exert anti-inflammatory effects in numerous tissues via the activation of 
peroxisome proliferator-activated receptors (PPARs), which regulates important cellular functions, 
such as glucose and lipid catabolism, cellular differentiation, proliferation and survival [41–43], and 
has been viewed as promising therapeutic target for bladder cancer [44]. Furthermore, the effects of 
statins, namely of atorvastatin, seem to be synergistically increased by cycloxygenase (COX)  
2 inhibitors [45], which was also effective in bladder cancer prevention in a previous study from our 
group, as well as in other studies [15,46]. This data reinforces the role played by inflammation in 
bladder carcinogenesis and the putative relevance of preventive strategies based on anti-inflammatory 
activity, such as demonstrated by atorvastatin in the present study.  
CD31 is a 130 kDa integral membrane protein, also known as PECAM-1 (platelet endothelial cell 
adhesion molecule-1), a member of the immunoglobulin superfamily, which mediates cell-to-cell 
adhesion, and is used as a marker of vascularization/angiogenesis. New vessels allow tumors to grow 
and cells to escape into the circulation and lodge in other organs. CD31 in bladder carcinoma has been 
correlated with the tumor grade and stage [47]. In our study, however, although a trend to higher 
expression of CD31 in the BBN group was found, no significant differences were found between 
groups. The tumor suppressor p53 has a key role in cancer, namely by regulating cell cycle 
progression, apoptosis, or senescence in response to various stress signals. Inactivation of the p53 
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pathway accounts for one of the most common molecular defects in human cancers, including in 
urothelial cancer [48]. Our data is in agreement with an impairment of p53 expression in bladder 
cancer, viewed by increased immunostaining in the BBN-treated rats, both in pre-neoplastic 
(hypertrophic) and neoplastic (papillary tumors) regions. This effect was clearly prevented in the 
Atorva + BBN-treated animals. Ki67 is a nuclear protein which is expressed in cycling cells but not in 
quiescent cells, thus representing a measurement of the tumor growth fraction and has been used in 
bladder cancer as an index of proliferative activity [49]. In our study, the BBN animals showed 
increased ki67 immunostaining, both in hypertrophic and neoplastic (papillary tumors) areas, 
suggesting a role for proliferation in tumor growth. Atorvastatin treatment prevented the effect, 
reinforcing an anti-proliferative effect of this drug in the nitrosamine-induced bladder cancer.  
The anti-inflammatory and anti-proliferative actions of atorvastatin were accompanied by a more 
beneficial redox status profile, demonstrated by the higher serum total antioxidant status and lower 
MDA/TAS ratio, most likely indicative of reduced reactive oxygen species (ROS) formation. Statins 
have been previously shown to have important anti-inflammatory, anti-proliferative and antioxidant 
properties [20–23]. Considering that these are key fuels for cancer development [50], and that 
antioxidant agents protect against bladder cell death [51], the inhibition of those pathways in very early 
stages of the carcinogenesis process seems to be crucial for the prevention of tumor growth.  
4. Experimental Section  
4.1. Animals and Groups 
Male Wistar rats, aged 10 weeks (weighing ca. 250 g), purchased from Charles River Lab. Inc. 
(Barcelona, Spain), were maintained in an air conditioned room, subjected to 12 h dark/light cycles 
and given standard laboratory rat chow (SAFE A-04, Augy, France) and free access to tap water. 
Animal experiments were conducted according to the European Communities Council Directives on 
Animal Care and approved by our National and Institution’s Ethics Committee for animal Research. 
The animals were divided into four groups: (1) Control group (n = 8): vehicle only; (2) Atorvastatin 
(Atorva) group (n = 8): 3 mg/kg bw/day of Atorvastatin (Zarator®, Pfizer, Lisbon, Portugal);  
(3) Carcinogen (BBN) group (n = 20): 0.05% of N-butyl-N-(4-hydroxybutyl)nitrosamine (Tokyo 
Chemical Industry Co., Ltd, Tokyo, Japan); (4) Preventive Atorvastatin group (n = 8): Atorva  
(3 mg/kg bw/day) + BBN. Treatments were performed in a two step protocol: Phase 1: week 1 to  
week 8, animals from groups 3 and 4 received BBN 0.05% ad libitum in drinking water. Atorva was 
given to groups 2 and 4; Phase 2: week 9 to 20, for study tumor expression or chemoprevention and 
underlying mechanisms. BBN was given in drinking water and Atorva (prepared in vehicle) was given 
by an esophageal cannula. All animals completed the 20-week study protocol. Body weight was 
measured weekly and drink beverage was monitored during the experimental period. 
4.2. Sample Collection and Preparation 
Blood: Before sacrifice, rats were anesthetized by intraperitoneal injection of 2 mg/Kg of a 2:1 (v/v) 
50 mg/mL Ketamine (Ketalar®, Parke-Davis, Pfizer Lab., Seixal, Portugal) solution in 2.5% 
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chlorpromazine (Largatil®, Rhône-Poulenc Rorer, Vitória lab., Amadora, Portugal). Blood samples 
were immediately collected from the jugular vein using needles with no anticoagulant.  
Tissues: Animals were sacrificed by cervical dislocation and the lungs, stomach, liver, kidneys and 
intestines were immediately removed, weighed and placed in ice-cold Krebs buffer or formaldehyde. 
Before removal, bladders were filled with a buffered formaldehyde solution and the urethra was tied, 
as pre-fixation for histological analysis. 
4.3. Tumor Chemoprevention Analysis 
4.3.1. Quantitative Analysis (Number and Tumor Volume) 
Each bladder pre-fixated in formaldehyde was carefully open; the lumen was inspected for grossly 
visible lesions and the number of tumors and tumor volume were reported in order to calculate the 
mean volume per rat and per tumor and the percentage of tumor per group.  
4.3.2. Qualitative Analysis (Bladder Histology) 
The bladder was immersion-fixed in 4% buffered formaldehyde and processed for paraffin 
sectioning. Three slices from each bladder were embedded and 3 μm thick sections were stained with 
haematoxylin & eosin (H & E) and examined for histology. 
4.4. Proliferation, Inflammation and Redox Status Markers 
Serum levels of TGF-β1 and TNF-α were measured through an ultrasensitive Quantikine® ELISA 
kits (R & D Systems, Minneapolis, USA). Serum CRP was measured by using an ELISA kit from 
Helica Biosystems, Inc. (Fullerton, CA, USA). The thiobarbituric acid reactive-species (TBARs) assay 
was used to evaluate serum lipid peroxidation, via MDA, and TAS in serum was measured through 
ferric reducing antioxidant potential (FRAP) assay, as previously described [52]. 
4.5. Bladder Cancer p53, ki67 and CD31 Immunohistochemistry 
Immunohistochemical (IHC) staining of p53, ki67 and CD31 in bladder cancer tissue was 
performed in paraffin-embedded tissue, which was cut into 4 mm sections and mounted on polisinated 
slides, using standard staining procedures, as described previously [53–55]. For each case, a single 
representative slide was selected for staining and histologic evaluation. Briefly, slides were 
deparaffinised and hydrated with water. Antigen enhancement was performed by pre-treating with 
microwave heating in a citrate buffer, pH 6.00 (for three pulses of 5 min each at 250 W). The slides 
were washed three times, 2 min each, and then incubated with blocking serum for 10 min to block the 
nonspecific binding, and the excess of blocking serum was removed. Staining was performed using the 
primary monoclonal antibodies for p53, ki67 and CD31. An appropriate positive control was used in 
each staining run, and each slide was stained with a negative control obtained by omitting the primary 
antibody. Diaminobenzidine was used as chromogen. Standard procedures were used for visualisation 
and the intensity and/or percentage of positive staining in the dominant pattern within the tumor was 
graded on a semiquantitative scale (0–3), in which 0 is very low intensity and <25% of staining; 1 is 
Int. J. Mol. Sci. 2012, 13 8495 
 
 
mild and between 25 and 50%; 2 is moderate and between 50 and 75% and 3 is severe and >75% of 
staining. All slides were reviewed independently by 2 investigators blinded to the data. 
4.6. Biochemical Assays (Safety Profile) 
Serum creatinine, urea, AST, ALT and CK levels were assessed through automatic validated 
methods and equipments (Hitachi 717 analyser, Roche Diag. Inc., MA, USA). 
4.7. Statistical Analysis 
For statistical analysis we used the GraphPad Prism version 5.00 software from GraphPad Software 
(San Diego, California, USA). Results are means ± standard error of means (SEM). Comparisons 
between groups were performed using ANOVA with Bonferroni or Fisher post-hoc test. A p value less 
than 0.05 was considered statistically significant. 
5. Conclusions  
Our data shows the chemopreventive potential of an early atorvastatin treatment, due to its 
antioxidant, anti-proliferative and anti-inflammatory properties. This is particularly relevant for 
patients with bladder cancer risk factors as well as for those with previous episodes of bladder tumor, 
due to the high recurrence rates. In conclusion, apart from the known reduction of cardiovascular risk 
given by its anticholesterolaemic action, Atorvastatin might have further beneficial effects due to 
chemopreventive properties against of bladder cancer.  
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